BIONOR PHARMA ASA
STOCK EXCHANGE ANNOUNCEMENT
(Oslo, Norway, 23 November 2016)
Reference is made to the resolution by the EGM on 11 February 2016 to issue warrants to participants in the private placement and subsequent offering completed on 10 March 2016. The exercise price for the warrants is NOK 0.71 per share. The warrants expired on 30 November 2016. The Company received exercise of a total of 8624 warrants within the expiry of the exercise period and will accordingly proceed to issue 8,624 new shares at a subscription price of NOK 0.71 per share. The share capital of the Company will be increased by NOK 862.40 as a consequence of the warrant exercise.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Einar J. Greve Chairman of the Board, Bionor Pharma ASA E-mail: email@example.com Cell Phone: +47 900 27 766
Unni Hjelmaas Acting Chief Executive Officer, Bionor Pharma ASA E-mail: firstname.lastname@example.org Cell Phone: +47 915 19 651
Last updated on: 02/12/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.